Trial Profile
An open-label, uncontrolled, multi-centre phase II combination study to investigate efficacy and safety of ONO-4538 in advanced melanoma patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Acral lentiginous melanoma; Malignant melanoma
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb; Ono Pharmaceutical
- 14 Nov 2018 Results published in the European Journal of Cancer
- 25 May 2018 The combination of Opdivo and Yervoy, has been approved in Japan, according to an Ono Pharmaceuticals media release.
- 29 Sep 2017 According to an Ono Pharmaceuticals media release, the company has submitted a supplemental application for Opdivo and Yervoy combination for the treatment of unresectable melanoma in Japan. The application is bases on results from this and phase III CheckMate-067 clinical trials.